Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood

Volumn 124, Issue 3, 2014, Pages 385-392

  Frankel, Arthur E ^a   Woo, Jung H ^b   Ahn, Chul ^a   Pemmaraju, Naveen ^c   Medeiros, Bruno C ^d   Carraway, Hetty E ^e   Frankfurt, Olga ^f   Forman, Stephen J ^g   Yang, Xuezhong A ^h   Konopleva, Marina ^c   Garnache Ottou, Francine ⁱ   Angelot Delettre, Fanny ⁱ   Brooks, Christopher ^j   Szarek, Michael ^j   Rowinsky, Eric ^j  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h Bon Secours St Francis Hospital   (United States)

ⁱ France   (France)

^j Stemline Therapeutics Inc ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DIPHENHYDRAMINE; DIPHTHERIA TOXOID; FAMOTIDINE; INTERLEUKIN 3 RECEPTOR; METHYLPREDNISOLONE; PARACETAMOL; PETHIDINE; RECOMBINANT PROTEIN; SERUM ALBUMIN; SL 401 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RECURRENCE; CATALYST; CHILL; CLINICAL ARTICLE; CLINICAL EVALUATION; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; LEUKEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMACYTOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SINGLE DRUG DOSE; TACHYCARDIA; THROMBOCYTOPENIA; TRANSLOCATION LINE; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA;

ADULT; AGED; DENDRITIC CELLS; DIPHTHERIA TOXIN; HEMATOLOGIC NEOPLASMS; HUMANS; INTERLEUKIN-3; MALE; MOLECULAR TARGETED THERAPY; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-3; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84904465235     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-566737     Document Type: Article

References (48)

1. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1006-1012.
2. Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-586.
3. Roos-Weil D, Dietrich S, Boumendil A, et al European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440-446.
4. Pagano L, Valentini CG, Pulsoni A, et al GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-246.
5. Menezes J, Acquadro F, Wiseman M, et al; Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-829.
6. Sapienza MR, Fuligni F, Agostinelli C, et al; Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition [published online ahead of print February 7, 2014]. Leukemia. doi:10.1038/leu.2014.64.
7. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055-1061.
8. Garnache-Ottou F, Feuillard J, Ferrand C, et al; GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-636.
9. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-3217.
10. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777-1784.
11. Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575-581.
12. Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002;2(1):19-36. (Pubitemid 34627376)
13. Jedema I, Barge RM, Frankel AE, Willemze R, Falkenburg JH. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. Exp Hematol. 2004;32(2):188-194. (Pubitemid 38177644)
14. Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 1998;9(4):490-496. (Pubitemid 28338764)
15. Delettre F, Frankel AE, Seilles E, et al. Preclinical studies of SL-401, a targeted therapy directed to the interleukin-3 receptor (IL3-R), in blastic plasmacytoid dendritic cell neoplasm (BPDCN): potent activity in BPDCN cell lines, primary tumor, and in an in vivo model. Blood. 2013;122(21):3942.
16. Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543-553. (Pubitemid 351298340)
17. Frankel AE, Konopleva M, Hogge D, et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. J Clin Oncol. 2013;31(15 Suppl):7029.
18. 388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005;54(8):799-806.
19. Urieto JO, Liu T, Black JH, et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004;33(1):123-133. (Pubitemid 38069820)
20. Cheson BD, Bennett JM, Kopecky KJ, et al International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
21. Cheson BD. New response criteria for lymphomas in clinical trials. Ann Oncol. 2008;19(Suppl 4):iv35-iv38.
22. Hall PD, Virella G, Beckham W, et al. Adult AML patients treated with DTGM diphtheria fusion toxin do not have neutralizing antibodies before or after the first treatment course. Clin Immunol. 2001;100(2):191-197.
23. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4.
24. Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res. 2001;25(10):875-881. (Pubitemid 32780509)
25. Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood. 2006;108(10):3530- 3537.
26. Horita H, Frankel AE, Thorburn A. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death. Leukemia. 2008;22(3):652-655. (Pubitemid 351386742)
27. Sanz AB, Sanchez-Niño MD, Izquierdo MC, et al. Macrophages and recently identified forms of cell death. Int Rev Immunol. 2014;33(1):9-22.
28. Osaki Y, Yokohama A, Saito A, et al. Characterization of CD561 dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? PLoS ONE. 2013;8(11):e81722.
29. Talpur R, Duvic M. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2012;12(3):180-185.
30. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13(17):5144-5149. (Pubitemid 47502082)
31. Lindstrom AL, Erlandsen SL, Kersey JH, Pennell CA. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood. 1997;90(6):2323-2334. (Pubitemid 27392716)
32. Baluna R, Vitetta ES. An in vivo model to study immunotoxin-induced vascular leak in human tissue. J Immunother. 1999;22(1):41-47. (Pubitemid 29042289)
33. Westcott MM, Abi-Habib RJ, Cohen KA, et al. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther. 2004;3(12):1681-1689. (Pubitemid 40136724)
34. Chen TW, Hwang SM, Chu IM, Hsu SC, Hsieh TB, Yao CL. Characterization and transplantation of induced megakaryocytes from hematopoietic stem cells for rapid platelet recovery by a two-step serum-free procedure. Exp Hematol. 2009;37(11):1330-1339, e5.
35. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002;8(5):1004-1013. (Pubitemid 34517633)
36. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376-388. (Pubitemid 32112849)
37. Baccala R, Gonzalez-Quintial R, Blasius AL, et al. Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus. Proc Natl Acad Sci USA. 2013;110(8):2940-2945.
38. Liu TF, Urieto JO, Moore JE, et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol. 2004;32(3):277-281. (Pubitemid 38328533)
39. Nievergall E, Ramshaw HS, Yong ASM, et al. Monoclonal antibody targeting of IL-3 receptor a with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123(8):1218-1228.
40. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138-3148.
41. Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161(3):389-401.
42. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30(6):607-613. (Pubitemid 47229695)
43. Stein C, Kellner C, Kügler M, et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol. 2010;148(6):879-889.
44. Leyton JV, Hu M, Gao C, et al. Auger electron radioimmunotherapeutic agent specific for the CD1231/CD131- phenotype of the leukemia stem cell population. J Nucl Med. 2011;52(9):1465-1473.
45. Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res. 2004;28(11):1221-1226. (Pubitemid 39243249)
46. Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res. 2010;34(8):1035- 1042.
47. Ray A, Das DS, Tian Z, et al. SL-401, a novel targeted therapy directed to the interleukin-3 receptor (IL-3R), inhibits plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and overcomes drug resistance. Blood. 2013;122(21):3170.
48. Brooks C, Macri V, Albini A, et al. SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), possesses preclinical cytotoxic activity against chronic eosinophilic leukemia. Blood. 2013;122(21):4104.